Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpressionNana Sasaki, Masafumi Taniwaki, Mio Yamamoto et al.|Experimental Hematology|2011Cited by 33
Frequent Involvement of PVT1 in Multiple Myeloma Carrying 8q24 Rearrangement and Identification of Novel PVT1-NBEA Chimeric Gene,Hisao Nagoshi, Masafumi Taniwaki, Tomohiko Taki et al.|Blood|2011Cited by 1